NCT04514484 2026-03-18Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVNational Cancer Institute (NCI)Phase 1 Active not recruiting8 enrolled
NCT03899792 2026-01-06LIBRETTO-121Eli Lilly and CompanyPhase 1/2 Active not recruiting36 enrolled 13 charts 2 FDA